Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2024-05-21 Earnings Release
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AstraZeneca to deliver $80bn revenue by 2030
Earnings Release Classification · 1% confidence The document starts with 'RNS Number' and is distributed via 'RNS, the news service of the London Stock Exchange'. It announces significant forward-looking strategic goals ('ambition to deliver $80 billion Total Revenue by 2030') and provides details about an upcoming Investor Day webcast. This is a broad, material announcement to the market, typical of a regulatory news service release. Since it is not a full financial report (like 10-K or IR), nor a specific announcement like a dividend (DIV) or director dealing (DIRS), and it is clearly a general regulatory disclosure distributed via RNS, the most appropriate classification is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on long-term strategy rather than period results, and it is not a Report Publication Announcement (RPA) because it is the primary announcement of strategic news, not just an announcement that a separate report is available. Q1 2024
2024-05-21 English
ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE
Foreign Filer Report
2024-05-20 English
AstraZeneca to manufacture ADCs in Singapore
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 0014P' and contains a press release format announcing a major investment ($1.5 billion manufacturing facility in Singapore) and strategic plans. It concludes with standard boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and 'Primary Information Provider'. This structure strongly indicates a general regulatory announcement disseminated via the RNS system, which is not covered by more specific categories like ER, 10-K, or CAP (as it's an investment/construction announcement, not a financing event like issuing shares or debt). Since it is a general regulatory announcement that doesn't fit the specific definitions (like DIRS, DIV, ER, etc.), the appropriate fallback category is Regulatory Filings (RNS). The document length (4762 chars) is substantial enough to be the primary announcement itself, not just a notice of publication.
2024-05-20 English
SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT
Foreign Filer Report
2024-05-16 English
SUPERNOVA Trial Met COVID-19 prevention endpoint
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated May 16, 2024. The content announces positive high-level results from the SUPERNOVA Phase III trial regarding sipavibart for COVID-19 prevention. It includes quotes from company executives and investigators, details about the trial design, and notes that the data 'will be presented at a forthcoming medical meeting' and that AstraZeneca is in dialogue with regulatory authorities. This structure—a brief announcement of clinical trial results and next steps, disseminated via the RNS system—is characteristic of a general regulatory announcement rather than a full financial report (10-K, IR) or a detailed presentation (IP). Since it is a specific, time-sensitive announcement distributed through the official regulatory news service (RNS), the most appropriate classification is Regulatory Filings (RNS), as it serves as the primary channel for such corporate updates that don't fit other specific categories like ER or DIV.
2024-05-16 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2024-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.